Lineage Other Liab from 2010 to 2025

LCTX Stock  USD 0.56  0.01  1.75%   
Lineage Cell Other Liabilities yearly trend continues to be fairly stable with very little volatility. Other Liabilities is likely to outpace its year average in 2025. During the period from 2010 to 2025, Lineage Cell Other Liabilities regression line of annual values had r-squared of  0.68 and arithmetic mean of  11,084,848. View All Fundamentals
 
Other Liabilities  
First Reported
2010-12-31
Previous Quarter
34.3 M
Current Value
36 M
Quarterly Volatility
15.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lineage Cell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lineage Cell's main balance sheet or income statement drivers, such as Depreciation And Amortization of 922.5 K, Interest Expense of 6 M or Total Revenue of 10.8 M, as well as many indicators such as Price To Sales Ratio of 22.99, Dividend Yield of 0.0015 or PTB Ratio of 2.8. Lineage financial statements analysis is a perfect complement when working with Lineage Cell Valuation or Volatility modules.
  
Check out the analysis of Lineage Cell Correlation against competitors.

Latest Lineage Cell's Other Liab Growth Pattern

Below is the plot of the Other Liab of Lineage Cell Therapeutics over the last few years. It is Lineage Cell's Other Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lineage Cell's overall financial position and show how it may be relating to other accounts over time.
Other Liab10 Years Trend
Slightly volatile
   Other Liab   
644.3.8M2.5M34.629.834.336.0489%-34%1275%-14%15%5%100%
       Timeline  

Lineage Other Liab Regression Statistics

Arithmetic Mean11,084,848
Geometric Mean2,840,377
Coefficient Of Variation137.81
Mean Deviation13,625,291
Median930,000
Standard Deviation15,276,037
Sample Variance233.4T
Range35.6M
R-Value0.82
Mean Square Error80T
R-Squared0.68
Significance0.000085
Slope2,645,645
Total Sum of Squares3500.4T

Lineage Other Liab History

202536 M
202434.3 M
202229.8 M
202134.6 M
20202.5 M
20193.8 M
2018644 K

About Lineage Cell Financial Statements

Lineage Cell investors use historical fundamental indicators, such as Lineage Cell's Other Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lineage Cell. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Liabilities34.3 M36 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lineage Stock Analysis

When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.

Trending Assets

CHRS
Coherus BioSciences
1.11  0.03  2.78 
NXTC
NextCure
0.78  0.01  1.30 
ARMP
Armata Pharmaceuticals
1.99  -0.09  -4.33 
SPRO
Spero Therapeutics
0.78  -0.01  -1.27 
MAIA
MAIA Biotechnology
1.88  -0.09  -4.57 
GOSS
Gossamer Bio
1.23  0.04  3.36 
REPL
Replimune Group
12.68  0.04  0.32 
KRON
Kronos Bio
0.98  0.02  2.08 
PRTG
Portage Biotech
4.51  0.17  3.92 
CNTB
Connect Biopharma
0.91  0.01  1.11 
NLTX
Neoleukin Therapeutics
0.00  0.00  0.00 
ONTTF
Oxford Nanopore Tech
1.41  0.02  1.44 
NUVB
Nuvation Bio
1.97  -0.01  -0.51 
BOLT
Bolt Biotherapeutics
0.47  -0.01  -2.08 
AGE
AGE Old
0.00  0.00  0.00 
ICCC
ImmuCell
5.28  -0.07  -1.31 
GRCL
Gracell Biotechnologies
0.00  0.00  0.00 
FREQ
Frequency Therapeutics
0.00  0.00  0.00 
LYRA
Lyra Therapeutics
0.21  0.01  5.00 
CVKD
Cadrenal Therapeutics,
19.00  0.59  3.20